Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial
Titel:
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial
Auteur:
Mills, Anthony M Rizzardini, Giuliano Ramgopal, Moti N Osiyemi, Olayemi O Bogner, Johannes R Hagins, Debbie P Paredes, Roger Reynes, Jacques Rockstroh, Jürgen K Carr, Andrew Su, Feng-Hsiu Klopfer, Stephanie O Eves, Karen Plank, Rebeca M Correll, Todd Fox, Michelle C